Gene Therapy for HCM Published on February 2, 2022 by hcmbeat A recent article on Biospace.com describes a method of targeted gene therapy for HCM patients currently being developed by Tenaya Therapeutics. This therapy is intended for patients whose HCM is caused by a mutation in the MYBPC3 gene. According to Tenaya CEO Faraz Ali, animal models show that this therapy can reverse declining heart function. You can find more information on about Tenaya’s approach here. Share this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to email a link to a friend (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Pinterest (Opens in new window)MoreClick to print (Opens in new window)Like this:Like Loading...
HCM Beat 